Meta-Analysis of Structural Magnetic Resonance Imaging (sMRI) Biomarkers in Schizophrenia Medication Trials

In order to determine the quality of evidence to support the application of imaging biomarkers in clinical trials of schizophrenia relevant sMRI literature was reviewed. A prior qualitative review following criteria by Altar et al (2008) suggested an evidence rating of “A-/B+” for sMRI in relation to medication effects. In order to provide a more quantitative evaluation a meta-analysis was undertaken to examine approved antipsychotic medication trials with at least one pre and post sMRI assessment.